Haematology and clinical chemistry, Vitamin Status B65 B83 B54 B74
Conditions
Interventions
Group 1: German giving birth mothers and their newborns. The mothers are interviewed by means of a questionnaire on topics such as allergy, abnormalities during pregnancy, known illnesses, etc.
About
Sponsors
Institut für Mikrobiologie, Immunologie und Hygiene, Technische Universität München
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: - Presence of written consent - Age > 18 years - feminine - Persons who are legally competent and mentally able to understand and follow the instructions of the study staff. - Patient information and written declaration of consent of the test person - Adequate bone marrow reserve with a peripheral granulocyte count >1500/µl and platelet count >40.000/µl - No condition after recurrent thrombosis or pulmonary embolism - no serious abnormalities during the physical examination - Documentation of known anaphylaxias
Exclusion criteria
Exclusion criteria: - Presence of the following autoimmune diseases: Anti-phospholipid, antibody syndrome, Goodpasture syndrome, Sjögren syndrome, rheumatoid arthritis, lupus erythematosus, sarcoidosis, anti-neutrophilic cytoplasmic antibodies (ANCA syndrome), scleroderma, chronic polychondritis - The following known immunodepressing diseases: X-chromosomal A-?-Globulinemia, severe combined immunodeficiency (SCID), common variable immunedeficiency (CVID), selective IgA deficiency - known hepatitis B and/or C, HIV, HSV, CMV, syphilis, toxoplasmosis infection - other, severe, active infection - ongoing corticosteroid treatment - transfusion-dependent anemia - any other disease or medical treatment which, in the opinion of the investigator, would militate against participation in the study, e.g. (pre-)eclampsia, HELLP syndrome - Persons who have a dependent/labour relationship with the sponsor or investigator. - known cancers currently or in the past
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inclusion of the German and Gabonese cohorts and analysis of certain genes in the placenta and blood. First endpoint December 2017. | — |
Secondary
| Measure | Time frame |
|---|---|
| Genetic analysis of placenta samples, immunological examination of blood samples. Second endpoint: April 2019. | — |
Countries
Gabon, Germany
Contacts
Public ContactClarissa Prazeres da Costa
Institut für Medizinische Mikrobiologie, Immunologie und Hygiene
Outcome results
None listed